This post was originally published on this site
Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines that are currently in various stages of development.
Analysts led by Tazeen Ahmad reiterated their $239 price target on the stock BNTX, which is 28.5% above its current price, and said the German company’s roughly 16 billion euros in cash is a positive.
“The…
